ABNX — Abionyx Pharma SA Share News
0.000.00%
Last trade - 00:00- €62.99m
- €51.30m
- €4.06m
Brief: Abionyx Pharma Receives FDA Orphan Drug Designation (Odd) For Cer-001 For The Treatment Of Lcat Deficiency Presenting As Kidney Dysfunction And/Or Ophthalmologic Disease
Brief: Abionyx Pharma Receives FDA Orphan Drug Designation For CER-001 For LCAT Deficiency
Abionyx jumps on 'promising' findings for COVID-19 treatment candidate
French and Benelux stocks-Factors to watch
French and Benelux stocks-Factors to watch
Brief: Abionyx Announces Positive Clinical Findings For CER-001 In Treating Covid-19
Brief: Abionyx Pharma FY Total Revenue At 0.67 Million Euros
Abionyx Pharma soars after approval for COVID-19 treatment
French and Benelux stocks-Factors to watch Jan 4
Brief: Abionyx Pharma Receives Compassionate Access Authorization By French Drug Safety Agency
Brief: Iris Pharma Becomes A Subsidiary Of Abionyx Pharma
Brief: Abionyx Completes Capital Increase At EUR 3.60 Per Share
Abionyx shares shoot up on deal to buy IRIS Pharma
French and Benelux stocks-Factors to watch
France's Abionyx to buy IRIS Pharma Holding, expand into ophthalmology (updated)
France's Abionyx to buy IRIS Pharma Holding
Brief: Abionyx Pharma Signs Agreement To Buy IRIS Pharma Holding
Abionyx Pharma jumps on new CER-001 results in kidney disease
Brief: Abionyx Says Positive Clinical Results For CER-001 In Kidney Disease Associated With LCAT Deficiency